3-(4-(甲硫基)苯基)丙酸甲酯 | 123392-44-9

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 3-(4-(甲硫基)苯基)丙酸甲酯
• 英文名称: methyl 3-(4-(methylthio)phenyl)propanoate
• 英文别名: methyl 3-(4-methylsulfanylphenyl)propanoate
• CAS: 123392-44-9
• 化学式: C₁₁H₁₄O₂S
• 分子量: 210.297
• InChiKey: LXZAFOHXMUDYNN-UHFFFAOYSA-N

物化性质

• 沸点：
  303.6±25.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-(甲硫基)苯基)丙酸甲酯 在 吡啶 、 sodium methylate 、 copper(ll) bromide 作用下， 以 甲醇 、 乙醇 、 氯仿 、 乙酸乙酯 为溶剂， 反应 32.0h， 生成 ethyl 2-(acetylamino)-5-[4-(methylthio)benzyl]-1,3-thiazole-4-carboxylate
  参考文献：
  名称：

  Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema: Part 2

  摘要：

  Novel thiazole derivatives were synthesized and evaluated as vascular adhesion protein-1 (VAP-1) inhibitors. Although our previous compound 1 showed potent VAP-1 inhibitory activity, the activity differed between humans and rats. This issue was overcome by a hybrid design using human VAP-1 specific inhibitor 2, which was found by high-throughput screening (HTS), a docking study of a human VAP-1 homology model, and an analysis of sequence information for humans and rats. As a result, we identified compound 35c, which showed strong VAP-1 inhibitory activity (human IC50 of 20 nM; rat IC50 of 72 nM) and significant inhibitory effects in the ex vivo test. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.02.048
• 作为产物：
  描述：

  4-Methylmercapto-zimtsaeure 在 palladium on activated charcoal 硫酸 、 氢气 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 168.0h， 生成 3-(4-(甲硫基)苯基)丙酸甲酯
  参考文献：
  名称：

  评价吸附在TiO2表面上的芳香族化合物的光催化单电子氧化反应的效率。

  摘要：

  在4-（甲硫基）苯基发色团与TiO2表面上的羧酸盐结合基团之间具有亚甲基桥接基团（-（CH2）n-，n = 0-4）的芳族硫化物的TiO2光催化单电子氧化机理已通过时间分辨漫反射（TDR）光谱研究了在乙腈（MeCN）中制浆的粉末。根据基质（S）和TiO2表面的电荷转移（CT）配合物的光谱特性估算，空穴供体和受体之间的电子耦合元素（H（DA））呈指数下降趋势。确定的9 nm（-1）的衰减因子β还支持4-（甲硫基）苯基发色团与TiO2表面分离的事实。

  DOI：

  10.1002/chem.200400516

文献信息

• Development of a Modified Bouveault–Blanc Reduction for the Selective Synthesis of α,α-Dideuterio Alcohols
  作者：Minhui Han、Xiaodong Ma、Shangchu Yao、Yuxuan Ding、Zihan Yan、Adila Adijiang、Yufei Wu、Hengzhao Li、Yuntong Zhang、Peng Lei、Yun Ling、Jie An

  DOI：10.1021/acs.joc.6b02950

  日期：2017.1.20

  α-dideuterio alcohols from carboxylic acid esters. Sodium dispersions are used as the electron donor in this electron transfer reaction, and ethanol-d1 is employed as the deuterium source. This reaction uses stable, cheap, and commercially available reagents, is operationally simple, and results in excellent deuterium incorporation across a broad range of aliphatic esters, which provides an attractive

  已开发出一种改进的Bouveault-Blanc还原方法，用于从羧酸酯合成α，α-二氘代醇。在该电子转移反应中，将钠分散液用作电子给体，将乙醇-d 1用作氘源。该反应使用稳定，便宜且可商购的试剂，操作简单，并且可在各种脂族酯中实现出色的氘掺入，为昂贵的发火性碱金属氘化物介导的反应提供了有吸引力的替代方法。
• NOVEL PYRAZINE AMIDE COMPOUNDS
  申请人：WIEDENMAYER Dieter

  公开号：US20150045326A1

  公开（公告）日：2015-02-12

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 5 , R 4 , R 5 , R 6 and X − have the meanings as indicated in the specification, to their use as a medicament, to their use in the treatment of a disease selected from among respiratory diseases or complaints and allergic diseases of the airways, to pharmaceutical composition comprising at least one of said compound or a pharmaceutically acceptable salt thereof, as well as to medicament combinations containing one or more of said compounds or a pharmaceutically acceptable salt thereof.

  本发明涉及式1的化合物或其药用盐，其中R1、R2、R3、R4、R5、R6和X-的含义如规范中所示，以及它们作为药物的用途，用于治疗呼吸道疾病或疾病和过敏性呼吸道疾病中选择的疾病，包括至少一种所述化合物或其药用盐的药物组合的制药组合。
• [EN] NOVEL PYRAZINE AMIDE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS PYRAZINE-AMIDES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015018754A1

  公开（公告）日：2015-02-12

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R6 and X- have one of the meanings as indicated in the specification, to their use as a medicament, to their use in the treatment of a disease selected from among respiratory diseases or complaints and allergic diseases of the airways, to pharmaceutical composition comprising at least one of said compound or a pharmaceutically acceptable salt thereof, as well as to medicament combinations containing one or more of said compounds or a pharmaceutically acceptable salt thereof.

  本发明涉及式1的化合物或其药用盐，其中R1、R2、R3、R5、R6和X-具有规范中指示的含义之一，其用作药物，用于治疗呼吸道疾病或疾病和过敏性疾病，包括至少一种所述化合物或其药用盐的药物组合的制药组合。
• Evaluating a Sodium Dispersion Reagent for the Bouveault–Blanc Reduction of Esters
  作者：Jie An、D. Neil Work、Craig Kenyon、David J. Procter

  DOI：10.1021/jo501093g

  日期：2014.7.18

  A new sodium dispersion reagent has been evaluated for the reduction of esters. Na-D15, a sodium dispersion with sodium particle size of 5–15 μm, is a nonpyrophoric reagent that can be handled in air. In this study, a broad range of aliphatic ester substrates were reduced to primary alcohols by Na-D15/i-PrOH with good yields. The method compares favorably with modern metal hydride reductions and is

  已经评估了一种新的钠分散剂用于酯的还原。Na-D15是钠粒子大小为5–15μm的钠分散液，是一种非生火试剂，可以在空气中处理。在这项研究中，Na-D15 / i -PrOH可以将多种脂族酯底物还原为伯醇，并具有良好的收率。与传统的金属氢化物还原相比，该方法具有优势，并且比传统的Bouveault-Blanc还原安全，有效得多。
• [EN] THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS<br/>[FR] DERIVES DE THIAZOLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE VAP-1
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2004067521A1

  公开（公告）日：2004-08-12

  A compound of the formula (I): R1-NH-X-Y-Z (I) wherein R1 is acyl; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond, lower alkylene or -COHN-; and Z is a groupe of the formulae (II) or (III) wherein R2 is a specified substituent or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor for preventing or treating a VAP-1associated disease, especially macular edema.

  一种化合物的分子式（I）：R1-NH-X-Y-Z（I），其中R1为酰基；X为可选取代噻唑衍生的双价残基；Y为键，较低的烷基或-COHN-；Z为分子式（II）或（III）中的基团，其中R2为特定的取代基或其药用可接受的盐，用作预防或治疗与血管粘附蛋白-1（VAP-1）相关的疾病的VAP-1抑制剂，特别是黄斑水肿。